<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/OBJECTIVES: Patients with implantable cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) often receive an adjunctive anti-arrhythmic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>We propose that an addition of <z:chebi fb="0" ids="9241">spironolactone</z:chebi> will reduce the number of clinically significant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-related therapies </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: In a multicentre retrospective study, 64 patients with ischaemic and non-ischaemic <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> whose left ventricular ejection fraction (LVEF) was &lt;35% and with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> were selected </plain></SENT>
<SENT sid="3" pm="."><plain>Amongst these patients, 28 patients were on <z:chebi fb="0" ids="9241">spironolactone</z:chebi> and 36 were not taking <z:chebi fb="0" ids="9241">spironolactone</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interrogation data were analysed for a maximum of 12 months </plain></SENT>
<SENT sid="5" pm="."><plain>Wilcoxon Rank Sum test was used to compare the study and control groups </plain></SENT>
<SENT sid="6" pm="."><plain>The outcomes were: (1) the number of shocks/anti-<z:hpo ids='HP_0001649'>tachycardia</z:hpo> pacing (ATP) episodes and (2) the number of <z:hpo ids='HP_0005141'>episodes of ventricular tachycardia</z:hpo> (VT) requiring ATP, non-sustained VT (NSVT), and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) over the study period </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:chebi fb="0" ids="9241">spironolactone</z:chebi> group had fewer monthly, VTs (P=0.027) (requiring ATP) </plain></SENT>
<SENT sid="8" pm="."><plain>The two groups did not differ in the number of NSVT or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> per month </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Addition of <z:chebi fb="0" ids="9241">spironolactone</z:chebi> as an adjunct to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) reduces VT requiring ATP, but does not affect NSVT or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> per month </plain></SENT>
</text></document>